medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2019, Number 1

<< Back Next >>

Ann Hepatol 2019; 18 (1)

Experience with Sorafenib in 3 Hospitals in Sao Paulo

Camargo-Pinheiro-Alves R, Viera-Alves E, Malzyner A, Gampel O, Almeida-Costa TF, Guz B, Poletti P

Language: English
References: 25
Page: 172-176
PDF size: 135.07 Kb.


ABSTRACT

Introduction and aim. Sorafenib has been the standard of care for first-line treatment of advanced hepatocellular carcinoma, a complex disease that affects an extremely heterogenous population. Thereby requiring multidisciplinary individualized treatment strategies that match the disease characteristics and the patients’ specific needs. Material and methods. Data for 175 patients who received sorafenib for hepatocellular carcinoma in three different hospitals in Sao Paulo, Brazil over a span of nine years were retrospectively analyzed. Results. The median age was 62 years. Percentages of patients with Child-Pugh A, B and C liver cirrhosis were 61%, 31% and 5%, respectively. Approximately half of the patients had Barcelona Clinic Liver Cancer stage B disease, and the other half had stage C. The median treatment duration was 253 days. Sorafenib dose was reduced to 400 mg/day in 41% of the patients due to toxicity. Overall objective response rate as per Response Evaluation Criteria in Solid Tumors and its modified version was 39%. Patients who received transarterial chemoembolization (TACE) at any point during sorafenib therapy were significantly more likely to experience an objective response. After a median follow-up of 339 days, the median overall survival was 380 days. Child-Pugh cirrhosis, tumor response and concomitant chemoembolization were independent prognostic factors for overall survival in multivariate analysis. Conclusion. Our results suggest that, in experienced hands, sorafenib therapy may benefit carefully selected hepatocellular carcinoma patients for whom other therapies are initially contraindicated, including those patients with Child-Pugh B liver function and those patients who are subsequently treated with concomitant TACE.


REFERENCES

  1. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.

  2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, Oliveira AC, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.

  3. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.

  4. Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, et al. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. Int J Clin Pract 2014; 68: 609-17.

  5. Barman PM, Su GL. Limitations of the Barcelona Clinic Liver Cancer Staging System With a Focus on Transarterial Chemoembolization as a Key Modality for Treatment of Hepatocellular Carcinoma. Clin Liver Dis 2016; 7: 32-5.

  6. Sanyal A, Poklepovic A, Moyneur E, Barghout V. Populationbased risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin 2010; 26: 2183-91.

  7. Palmer DH, Hussain SA, Smith AJ, Hargreaves S, Ma YT, Hull D, Johnson PJ, et al. Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom. Br J Cancer 2013; 109: 888-90.

  8. Mellinger JL, Volk ML. Multidisciplinary management of patients with cirrhosis: a need for care coordination. Clin Gastroenterol Hepatol 2013; 11: 217-23.

  9. World Medical A. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013; 310: 2191-4.

  10. European Association For The Study Of The L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.

  11. Llovet JM, Fuster J, Bruix J, Barcelona-Clinic Liver Cancer G. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004; 10: s115- s120.

  12. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.

  13. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.

  14. Han SK, Lee D, Lee H, Kim D, Son HG, Yang JS, Lee SV, et al. OASIS 2: online application for survival analysis 2 with features for the analysis of maximal lifespan and healthspan in aging research. Oncotarget 2016; 7: 56147-52.

  15. Reig M, Torres F, Rodriguez-Lope C, Forner A, LLarch N, Rimola J, Darnell A, et al. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. J Hepatol 2014; 61: 318-24.

  16. Chiu J, Tang YF, Yao TJ, Wong A, Wong H, Leung R, Chan P, et al. The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits. Cancer 2012; 118: 5293-301.

  17. Woo HY, Heo J, Yoon KT, Kim GH, Kang DH, Song GA, Cho M. Clinical course of sorafenib treatment in patients with hepatocellular carcinoma. Scand J Gastroenterol 2012; 47: 809-19.

  18. Berk V, Kaplan MA, Tonyali O, Buyukberber S, Balakan O, Ozkan M, Demirci U, et al. Efficiency and side effects of sor afenib therapy for advanced hepatocellular carcinoma: a retrospective study by the anatolian society of medical oncology. Asian Pac J Cancer Prev 2013; 14: 7367-9.

  19. Kostner AH, Sorensen M, Olesen RK, Gronbaek H, Lassen U, Ladekarl M. Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability. Sci World J 2013; 2013: 931972.

  20. Zugazagoitia J, Manzano A, Sastre J, Ladero JM, Puente J, Diaz-Rubio E. Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function. Clin Transl Oncol 2013; 15: 146-53.

  21. Abdel-Rahman O, Abdelwahab M, Shaker M, Abdelwahab S, Elbassiony M, Ellithy M. Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience. J Egypt Natl Canc Inst 2014; 26: 9-13.

  22. Imedio ER, Beveridge RD, Urtasun JA, Campos GB, Estelles DL, Esparcia MF, Daroqui JC, et al. Safety and efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma: a single center experience. Med Oncol 2014; 3: 948.

  23. Lee SH, Song IH, Noh R, Kang HY, Kim SB, Ko SY, Lee ES, et al. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions. BMC Cancer 2015; 15: 236.

  24. Geschwind JF, Kudo M, Marrero JA, Venook AP, Chen XP, Bronowicki JP, Dagher L, et al. TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON. Radiology 2016; 279: 630-40.

  25. Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, Paik SW, et al. Sorafenib or placebo plus TACE with doxorubicin- eluting beads for intermediate stage HCC: The SPACE trial. J Hepatol 2016; 64: 1090-8.




2020     |     www.medigraphic.com